Clinical Trial Update: OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating once-daily versus thrice-daily dosing of mesalamine granules in active ulcerative colitis has completed. The sponsor is Dr. Falk Pharma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mesalamine Granules (mesalamine)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED